This is a non-core endpoint: only basic statistics are computed.
Carcinoma in situ, thyroid and other endocrine glands
CD2_INSITU_THYROICD2_ENDOCRINE_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D09
- Name in latin
- Carcinoma in situ glandulae thyreoideae
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ, thyroid and other endocrine glands
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ, thyroid and other endocrine glands
- Carcinoma in situ of other and unspecified sites
- Carcinoma in situ of other and unspecified sites
- In situ neoplasms
- In situ neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 11 | 9 | - |
| Unadjusted period prevalence (%) | 0.00 | 0.00 | - |
| Median age at first event (years) | 46.66 | 44.82 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3036535) Thyroglobulin [Mass/volume] in Serum or Plasma
6
0
+∞
6.92
4.3
0.0
—
—
—
0
0
(3025547) Thyroglobulin Ab [Units/volume] in Serum or Plasma
5
0
+∞
5.63
4.8
0.0
—
—
—
0
0
(3018418) pH of Serum or Plasma
6
23
4.47
1.65
4.3
4.8
—
7.4
—
0
5
(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma
11
76
+∞
1.48
8.5
3.9
pmol/l
17.9
14.8
4.82
11
67
(42870588) Differential panel, method unspecified - Blood
6
29
3.31
1.12
3.5
4.9
—
—
—
0
0
(3029937) Albumin [Presence] in Urine by Test strip
0
27
0.00
0.92
0.0
5.9
—
0.0
—
0
9
(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum
0
14
0.00
0.44
0.0
2.6
—
—
—
0
0
(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
0
17
0.00
0.44
0.0
1.8
—
433.6
—
0
10
(3009201) Thyrotropin [Units/volume] in Serum or Plasma
11
92
+∞
0.44
9.5
4.8
mu/l
0.7
1.9
4.79
11
78
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
5
40
1.45
0.27
4.2
4.7
—
—
—
0
0
(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
0
11
0.00
0.22
0.0
3.8
—
—
—
0
0
(3023103) Potassium [Moles/volume] in Serum or Plasma
11
99
+∞
0.22
15.6
13.8
mmol/l
4.0
4.0
0.12
11
93
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
0
10
0.00
0.22
0.0
2.9
—
—
—
0
0
(3020564) Creatinine [Moles/volume] in Serum or Plasma
11
98
+∞
0.22
16.5
14.0
umol/l
67.8
75.1
0.72
11
98
(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma
0
12
0.00
0.22
0.0
1.0
—
164.8
—
0
5
(3019550) Sodium [Moles/volume] in Serum or Plasma
11
97
+∞
0.22
15.5
14.0
mmol/l
140.7
139.7
1.00
11
92
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
0
9
0.00
0.00
0.0
2.8
—
—
—
0
0
(3021879) Hepatitis B virus core Ab [Presence] in Serum
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3014111) Lactate [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
5.6
—
1.4
—
0
5
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(40761536) Microorganisms panel - Urine sediment
0
9
0.00
0.00
0.0
5.6
—
—
—
0
0
(3016293) Bicarbonate [Moles/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
4.5
—
26.0
—
0
6
(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
11
102
+∞
0.00
6.5
8.9
u/l
24.7
23.4
0.13
11
94
(3022145) Colonoscopy Study observation
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
2.1
—
—
—
0
0
(3044889) 12 lead EKG panel
6
63
0.90
0.00
2.7
3.2
—
—
—
0
0
(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
5
47
1.12
0.00
1.4
2.2
nmol/l
59.0
81.9
—
5
39
(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
0
7
0.00
0.00
0.0
3.0
—
1.2
—
0
7
(3019832) Treponema pallidum Ab [Presence] in Serum
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
(3004716) Salmonella sp identified in Stool by Organism specific culture
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_THYROICD2_ENDOCRINE_EXALLC – Carcinoma in situ, thyroid and other endocrine glands
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).